Premium
Fully automated determination of eserine N ‐oxide in human plasma using on‐line solid‐phase extraction with liquid chromatography coupled with electrospray ionization tandem mass spectrometry
Author(s) -
Pruvost A.,
Ragueneau I.,
Ferry A.,
Jaillon P.,
Grognet J.M.,
Benech H.
Publication year - 2000
Publication title -
journal of mass spectrometry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 121
eISSN - 1096-9888
pISSN - 1076-5174
DOI - 10.1002/(sici)1096-9888(200005)35:5<625::aid-jms988>3.0.co;2-6
Subject(s) - chemistry , chromatography , electrospray ionization , selected reaction monitoring , solid phase extraction , tandem mass spectrometry , mass spectrometry , electrospray , detection limit , extraction (chemistry) , pharmacokinetics , liquid chromatography–mass spectrometry , medicine
A sensitive and entirely automated solid‐phase extraction/liquid chromatography/electrospray ionization tandem mass spectrometric (SPE/LC/ESI‐MS/MS) method was developed and validated for the determination of eserine N ‐oxide (ENO), a cholinesterase inhibitor‐like physostigmine in human plasma, for use in pharmacokinetic studies. ENO is light‐sensitive and the use of a fully on‐line process increased the reliability of the assay. Plasma samples previously mixed with neostigmine bromide to prevent in vitro degradation, and tacrine as internal standard (IS), were directly injected into the SPE/LC/ESI‐MS/MS system. MS software piloted the overall system. MS/MS detection of ENO and the IS was performed in the positive ion ESI mode using multiple reaction monitoring. The linear calibration curve for ENO ranged from 25 pg ml −1 to 12.5 ng ml −1 . The limit of quantitation was 25 pg ml −1 with 250 µl of plasma injected. Precision, accuracy and stability tests were within the acceptable range and just one analyst is required to analyze 50 unknown samples a day five days per week, from the preparation of the samples (i.e. thawing and centrifugation) to data processing. A pilot pharmacokinetic study in three healthy volunteers treated with 4.5 mg of ENO (Génésérine3 ® ) showed that the method was suitable for pharmacokinetic studies in humans. Copyright © 2000 John Wiley & Sons, Ltd.